Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
Abstract It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1c086d02fb67435ca602adcb170580af |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1c086d02fb67435ca602adcb170580af |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1c086d02fb67435ca602adcb170580af2021-12-02T16:45:41ZEfficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study10.1038/s41598-021-96089-x2045-2322https://doaj.org/article/1c086d02fb67435ca602adcb170580af2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96089-xhttps://doaj.org/toc/2045-2322Abstract It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC patients with Child–Pugh A were enrolled, and divided into the NAFLD/NASH (n = 103) and Viral/Alcohol (n = 427) groups. Clinical features were compared in a retrospective manner. Progression-free survival (PFS) was better in the NAFLD/NASH than the Viral/Alcohol group (median 9.3 vs. 7.5 months, P = 0.012), while there was no significant difference in overall survival (OS) (20.5 vs. 16.9 months, P = 0.057). In Cox-hazard analysis of prognostic factors for PFS, elevated ALT (≥ 30 U/L) (HR 1.247, P = 0.029), modified ALBI grade 2b (HR 1.236, P = 0.047), elevated AFP (≥ 400 ng/mL) (HR 1.294, P = 0.014), and NAFLD/NASH etiology (HR 0.763, P = 0.036) were significant prognostic factors. NAFLD/NASH etiology was not a significant prognostic factor in Cox-hazard analysis for OS (HR0.758, P = 0.092), whereas AFP (≥ 400 ng/mL) (HR 1.402, P = 0.009), BCLC C stage (HR 1.297, P = 0.035), later line use (HR 0.737, P = 0.014), and modified ALBI grade 2b (HR 1.875, P < 0.001) were significant. Lenvatinib can improve the prognosis of patients affected by u-HCC irrespective of HCC etiology or its line of treatment.Atsushi HiraokaTakashi KumadaToshifumi TadaJoji TaniKazuya KariyamaShinya FukunishiMasanori AtsukawaMasashi HirookaKunihiko TsujiToru IshikawaKoichi TakaguchiEi ItobayashiKazuto TajiriNoritomo ShimadaHiroshi ShibataHironori OchiKazuhito KawataSatoshi YasudaHidenori ToyodaTomoko AokiTakaaki TanakaHideko OhamaKazuhiro NousoAkemi TsutsuiTakuya NaganoNorio ItokawaTaeang AraiTomomi OkuboMichitaka ImaiYohei KoizumiShinichiro NakamuraKoji JokoYoichi HiasaMasatoshi KudoThe Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)Nature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Atsushi Hiraoka Takashi Kumada Toshifumi Tada Joji Tani Kazuya Kariyama Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Satoshi Yasuda Hidenori Toyoda Tomoko Aoki Takaaki Tanaka Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Taeang Arai Tomomi Okubo Michitaka Imai Yohei Koizumi Shinichiro Nakamura Koji Joko Yoichi Hiasa Masatoshi Kudo The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| description |
Abstract It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC patients with Child–Pugh A were enrolled, and divided into the NAFLD/NASH (n = 103) and Viral/Alcohol (n = 427) groups. Clinical features were compared in a retrospective manner. Progression-free survival (PFS) was better in the NAFLD/NASH than the Viral/Alcohol group (median 9.3 vs. 7.5 months, P = 0.012), while there was no significant difference in overall survival (OS) (20.5 vs. 16.9 months, P = 0.057). In Cox-hazard analysis of prognostic factors for PFS, elevated ALT (≥ 30 U/L) (HR 1.247, P = 0.029), modified ALBI grade 2b (HR 1.236, P = 0.047), elevated AFP (≥ 400 ng/mL) (HR 1.294, P = 0.014), and NAFLD/NASH etiology (HR 0.763, P = 0.036) were significant prognostic factors. NAFLD/NASH etiology was not a significant prognostic factor in Cox-hazard analysis for OS (HR0.758, P = 0.092), whereas AFP (≥ 400 ng/mL) (HR 1.402, P = 0.009), BCLC C stage (HR 1.297, P = 0.035), later line use (HR 0.737, P = 0.014), and modified ALBI grade 2b (HR 1.875, P < 0.001) were significant. Lenvatinib can improve the prognosis of patients affected by u-HCC irrespective of HCC etiology or its line of treatment. |
| format |
article |
| author |
Atsushi Hiraoka Takashi Kumada Toshifumi Tada Joji Tani Kazuya Kariyama Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Satoshi Yasuda Hidenori Toyoda Tomoko Aoki Takaaki Tanaka Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Taeang Arai Tomomi Okubo Michitaka Imai Yohei Koizumi Shinichiro Nakamura Koji Joko Yoichi Hiasa Masatoshi Kudo The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
| author_facet |
Atsushi Hiraoka Takashi Kumada Toshifumi Tada Joji Tani Kazuya Kariyama Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Satoshi Yasuda Hidenori Toyoda Tomoko Aoki Takaaki Tanaka Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Taeang Arai Tomomi Okubo Michitaka Imai Yohei Koizumi Shinichiro Nakamura Koji Joko Yoichi Hiasa Masatoshi Kudo The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
| author_sort |
Atsushi Hiraoka |
| title |
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| title_short |
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| title_full |
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| title_fullStr |
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| title_full_unstemmed |
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| title_sort |
efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/1c086d02fb67435ca602adcb170580af |
| work_keys_str_mv |
AT atsushihiraoka efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT takashikumada efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT toshifumitada efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT jojitani efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kazuyakariyama efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT shinyafukunishi efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT masanoriatsukawa efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT masashihirooka efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kunihikotsuji efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT toruishikawa efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT koichitakaguchi efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT eiitobayashi efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kazutotajiri efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT noritomoshimada efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT hiroshishibata efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT hironoriochi efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kazuhitokawata efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT satoshiyasuda efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT hidenoritoyoda efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT tomokoaoki efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT takaakitanaka efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT hidekoohama efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kazuhironouso efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT akemitsutsui efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT takuyanagano efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT norioitokawa efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT taeangarai efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT tomomiokubo efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT michitakaimai efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT yoheikoizumi efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT shinichironakamura efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT kojijoko efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT yoichihiasa efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT masatoshikudo efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy AT thereallifepracticeexpertsforhccrelpecstudygroupandhcc48grouphepatocellularcarcinomaexpertsfrom48clinicsinjapan efficacyoflenvatinibforunresectablehepatocellularcarcinomabasedonbackgroundliverdiseaseetiologymulticenterretrospectivestudy |
| _version_ |
1718383441360191488 |